Summary: Antipsychotic Medication

risperidone whereas in this one there was a fixed dose to limit breach in blinding and to facilitate comparison between similar groups, also having this fixed dosage helped prevent bias because when using a titrating schedule of dosing in a randomized trial, it tends to show bias toward a desired goal. Risperidone in this study was well tolerated and there weren’t significant differences in weight gain or sedation(13). One of the main things disliked about risperidone is its tendency to increase the incidence of dyskinesia and other extrapyramidal side effects. In this study only mild and transient dyskinesias were seen in only 3 children, however that could be due to the low fixed dosage(13) of the study.

4. What type of drug is chlorpromazine, and where was it first tested on patients? Antipsychotic, A new phenothiazine drug, chlorpromazine, was synthesized in France in 1950 and was tested on such patients. In 1952, two French psychiatrists, Delay and Deniker, announced that the drug exerted a specific effect in diminishing the symptoms and signs of psychosis in patients with severe mental illnesses. (Hart & Ksir, p. 171)

If the patient meets all requirements and is mentally stable, a prescription for the medication may be written and the patient may take the medication.

Perry, P. J., Alexander, B., Liskow, B. I., & DeVane, C. L. (2007). Psychotropic drug handbook (8th ed.). Philadelphia, PA: Lippincott Williams & Wilkins.

Jyllian Kemsley Ph.D. is a chemical research scientist, and scientific research contributor to the CENtral Science’s Safety Zone blog that seeks to “cover science and technology, business and industry, government and policy, education, and employment aspects of the chemistry field”. Her article entitled “Psychedelic Compounds like Ecstasy May Be Good for More than Just a High", reports on the revolutionary research theory within the field of medicine that seeks to examine the prospective benefits of using psychoactive compounds in treating a number of mental conditions. The piece is well written, and presents a number of background studies that have evaluated the efficiency of these

A research study was conducted by Dr. Helen Kales and others as to whether or not antipsychotic drugs increased mortality rate in elderly dementia patients. In her article in The American Journal of Psychiatry, Kales concluded, “Antipsychotic medications taken by patients with dementia were associated with higher mortality rates than were most other medications used for neuropsychiatric symptoms.” According to Dr. Lyketos, who did a presentation about dementia patients, “A few neuropsychiatric symptoms in dementia patients include: depression, sundowning, anxiety, repetitious questioning, and sleep disturbance” (Lyketos). Sundowning is one of the most common symptoms and occurs when the patient suffers “increased confusion and agitation at cyclic

For antipsychotics such as Thorazine, major risks to the patient include dependence and withdrawal (Correll, 2013). Therefore, I would ensure that patients take the right dosage of the drug promptly. Additionally, I would ensure that the drugs are administered by a medical practitioner who is licensed. An advantageous factor for antipsychotics is that they are not highly addictive. Also, I would influence the integration of cognitive therapy to prevent relapse and dependence. I would focus my education on all ages, while considering adults above 25 years of age who form the largest percentage of

In 1955, antipsychotic medications were introduced to help mental disorders. These medications are usually taken orally in which help relieve symptoms for periods of days. The misuse or abuse of the medications are low. There are three generations of antipsychotic medications. The first generation is known for reducing hallucinations and delusions, but not affecting problems like disorientation or depression. An example would be chlorpromazine, brand name being Thorazine. Some negative side effects of taking the first generation drugs are Parkinson’s-like symptoms, tardive dyskinesia, and weight gain. Next, the second generation drugs minimized the outcome of the individual getting Parkinson’s-like symptoms. An example of this generation would be Clozaril. “A unique feature of Clozaril is the 1 to 2 percent chance of developing a potentially lethal blood disease called agranulocytosis” (Levinthal 282). This disease decreases white blood cells and affects the immune system. If early signs of this disease start to appear the patient will stop taking Clozaril and recover. Lastly, the third generation has shown to be the most effective on schizophrenia. Abilify is an example of this generation drug. It does not have a risk of Parkinson’s, tardive dyskinesia, or diabetes. Abilify blocks specific serotonin receptors in which prevents negative side effects from happening. These different

As we have seen, treatment of schizophrenia with antipsychotic drugs can have impressive results in terms of decreasing active symptoms, although it does nothing to alleviate negative symptoms or to improve cognitive functioning. Unfortunately, this kind of treatment has the drawback of extremely serious and even fatal side-effects. Newer generation atypical antipsychotics offer more hope, as they can treat both active and negative symptoms, and also improve cognitive functioning. Moreover, they have fewer side-effects. However, treatment is complicated by the fact that results are unpredictable; and in addition the side-effects that they do have can be very serious, such as diabetes, which in itself is life-threatening. However, as the potential side-effects are known, the physician has leeway to choose a drug which is a good match for the patient’s clinical profile. Then, once the patient’s symptoms have been much alleviated with an appropriate newer generation atypical antipsychotic, the patient should be able to also benefit from a range of psychotherapeutic interventions. It is argued that this is the best treatment regime to choose, as it is likely to result in the greatest improvement in quality of life, coupled with the lowest risk of potentially devastating side-effects, or of death. This is likely to be better than utilizing cognitive behavioral therapy, the results of which are not reliably known – although research has certainly shown that it is less efficacious

It has come to my attention going over teacher files that one of my elementary teachers has a prescription for Risperdal, which is an anti-psychotic medication to treat schizophrenia. It is my job to decide what to do, and if she is a risk to the children if she stops taking her medications. There are a number of factors to consider before making a decision, as well as ethical issues to evaluate concerning this situation. In order to be morally sound in my decision I need to decide what the right action to take is. So first off, I need to get the facts on this medication.

Antipsychotics are generally used to treat psychosis in mental disorders. These disorders include schizophrenia and bipolar disorder (Thyssen et al., 2010). Risperidone is known as an atypical second generation antipsychotic and used in the treatment of a multitude of disorders. This medication can often challenge behavioral problems that are associated with schizophrenia, autism spectrum disorder, bipolar disorder, or attention deficit hyperactivity disorder (Schatzberg & Nemeroff, 2013). It is important for the prescriber to be aware of the side effect and any possible adverse reactions that may occur. There can be many detrimental side effects that someone may not enjoy,

Although Abilify has been around since it was approved in 2002 for the treatment of schizophrenia, the approval of such a digital pill-technology combo opens up a wide range of possibilities, even as pills continue to affect more lives each day. According to a 2015 study published in JAMA, the percentage of adults taking five or more prescription

Antipsychotics are classified as major tranquilizers that are used to treat mental health illnesses such as schizophrenia, bipolar disorder, and other mental illnesses. They can also treat severe depression and severe anxiety. These antipsychotics drugs reduce or increase the effect of neurotransmitters in the brain to regulate levels that help transfer information throughout the brain. The neurotransmitters that are affected are the serotonin, dopamine, and noradrenaline.

Iloperidone, a derivative of piperidinyl-benzisoxazole is an atypical antipsychotic drug. The specific indication for the drug is alleviation of psychotic symptoms and not schizophrenia. This is a noteworthy difference from the standard indications for the recently enlisted antipsychotic drugs as these indicate a clinical condition as opposed to a symptom happening in patients who have a clinical condition (for this situation, schizophrenia). This is the approach suggested in the TGA adopted European Union (EU) rule. Iloperidone binds with high antagonistic affinity to serotonin 5-HT1A, 5-HT2A and dopamine D2 and D3 receptors and moderately interacts with dopamine D4, serotonin 5-HT6 and 5-HT7 and adrenergic α1 and α2 receptors.

I like that you pointed out that we should show a delicate consideration to our friends and relatives who may be wanting to attain advice or answers from us concerning any drug therapy questions that they may have. I think that it is very important to let them know that we care about them and their questions, but that we are not qualified professionally to answer them. I would advise them to contact their doctor about getting answers to their questions and also their pharmacist. I would never want to give my opinion or advice on something and it be inaccurate information or something that is professionally unethical for me to do. I think pointing them to reliable, professionals for their medical concerns and questions is the most